Use and indications of cholestyramine and bile acid sequestrants

Internal and Emergency Medicine

Volumn 8, Issue 3, 2013, Pages 205-210

  Scaldaferri, Franco ^a   Pizzoferrato, Marco ^a   Ponziani, Francesca Romana ^a   Gasbarrini, Giovanni ^b   Gasbarrini, Antonio ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Fondazione Ricerca in Medicina ONLUS   (Italy)

Author keywords

Bile acid sequestrants; Cholestyramine; Colesevelam; Colestipol

Indexed keywords

EID: 84875759070     PISSN: 18280447     EISSN: 19709366     Source Type: Journal    
DOI: 10.1007/s11739-011-0653-0     Document Type: Review

References (50)

1. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol In Adults (2001) Executive summary of the third report of the national cholesterol education program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA 285(19): 2486-2497.
2. Di Padova C et al (1984) Double-blind placebo-controlled clinical trial of microporous cholestyramine in the treatment of intra- and extra-hepatic cholestasis: relationship between itching and serum bile acids. Methods Find Exp Clin Pharmacol 6(12): 773-776.
3. Staels B, Kuipers F (2007) Bile acid sequestrants and the treatment of type 2 diabetes mellitus. Drugs 67(10): 1383-1392.
4. Kobayashi M et al (2007) Prevention and treatment of obesity, insulin resistance, and diabetes by bile acid-binding resin. Diabetes 56(1): 239-247.
5. Kamal-Bahl SJ et al (2007) Discontinuation of lipid modifying drugs among commercially insured United States patients in recent clinical practice. Am J Cardiol 99(4): 530-534.
6. Reiner Z (2010) Combined therapy in the treatment of dyslipidemia. Fundam Clin Pharmacol 24(1): 19-28.
7. Bays H, Dujovne C (2003) Colesevelam HCl: a non-systemic lipid-altering drug. Expert Opin Pharmacother 4(5): 779-790.
8. Graham I et al (2007) European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil 14(Suppl 2): E1-E40.
9. Domanski M et al (2008) Pleiotropic effect of lovastatin, with and without cholestyramine, in the post coronary artery bypass graft (Post CABG) trial. Am J Cardiol 102(8): 1023-1027.
10. The Post Coronary Artery Bypass Graft Trial Investigators (1997) The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. N Engl J Med 336(3): 153-162.
11. Brown BG et al (1997) Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol < 100 mg/dl in patients with hyperlipidemia and coronary artery disease. Am J Cardiol 80(2): 111-115.
12. Whitney EJ et al (2005) A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events. Ann Intern Med 142(2): 95-104.
13. Ballantyne CM, Miller E, Chitra R (2004) Efficacy and safety of rosuvastatin alone and in combination with cholestyramine in patients with severe hypercholesterolemia: a randomized, open-label, multicenter trial. Clin Ther 26(11): 1855-1864.
14. Lal SM, Katyal A (2002) Effects of nicotinic acid and lovastatin in combination with cholestyramine in renal transplant patients. Mo Med 99(10): 580-584.
15. Bays HE et al (2006) Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 97(8): 1198-1205.
16. Davidson MH et al (2010) A 50-week extension study on the safety and efficacy of colesevelam in adults with primary hypercholesterolemia. Am J Cardiovasc Drugs 10(5): 305-314.
17. Bays H, Jones PH (2007) Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors. Vasc Health Risk Manag 3(5): 733-742.
18. Huijgen R et al (2010) Colesevelam added to combination therapy with a statin and ezetimibe in patients with familial hypercholesterolemia: a 12-week, multicenter, randomized, double-blind, controlled trial. Clin Ther 32(4): 615-625.
19. Bays H et al (2006) Lipid-lowering effects of colesevelam HCl in combination with ezetimibe. Curr Med Res Opin 22(11): 2191-2200.
20. Knopp RH et al (2006) Lipoprotein effects of combined ezetimibe and colesevelam hydrochloride versus ezetimibe alone in hypercholesterolemic subjects: a pilot study. Metabolism 55(12): 1697-1703.
21. Ballantyne CM et al (2003) Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation 107(19): 2409-2415.
22. Bays H et al (2008) Long-term (48-week) safety of ezetimibe 10 mg/day coadministered with simvastatin compared to simvastatin alone in patients with primary hypercholesterolemia. Curr Med Res Opin 24(10): 2953-2966.
23. Rivers SM et al (2007) Colesevelam hydrochloride-ezetimibe combination lipid-lowering therapy in patients with diabetes or metabolic syndrome and a history of statin intolerance. Endocr Pract 13(1): 11-16.
24. Harper CR, Jacobson TA (2010) Evidence-based management of statin myopathy. Curr Atheroscler Rep 12(5): 322-330.
25. Pusl T, Beuers U (2005) Extrahepatic manifestations of cholestatic liver diseases: pathogenesis and therapy. Clin Rev Allergy Immunol 28(2): 147-157.
26. Kremer AE et al (2008) Pathogenesis and treatment of pruritus in cholestasis. Drugs 68(15): 2163-2182.
27. Kuiper EM et al (2010) The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology 52: 1340-1344.
28. Longo M, Crosignani A, Podda M (2001) Hyperlipidemia in chronic cholestatic liver disease. Curr Treat Options Gastroenterol 4(2): 111-114.
29. Garg A, Grundy SM (1994) Cholestyramine therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. A short-term, double-blind, crossover trial. Ann Intern Med 121(6): 416-422.
30. Bays HE et al (2008) Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. Arch Intern Med 168(18): 1975-1983.
31. Fonseca VA et al (2008) Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care 31(8): 1479-1484.
32. Goldberg RB et al (2008) Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med 168(14): 1531-1540.
33. Brufau GKF, Prado K et al (2008) Altered bile acid metabolism in type 2 diabetes mellitus (T2DM). Diabetes 57(A435).
34. Ma K et al (2006) Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 116(4): 1102-1109.
35. Suzuki T et al (2007) Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch 74(5): 338-343.
36. Staels B, Fonseca VA (2009) Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration. Diabetes Care 32(Suppl 2): S237-S245.
37. Rosenstock J et al (2010) Initial combination therapy with metformin and colesevelam for achievement of glycemic and lipid goals in early type 2 diabetes. Endocr Pract 16(4): 629-640.
38. Thompson WG (1975) Treatment of cholerheic diarrhea with cholestyramine and a hydrophilic colloid. Dis Colon Rectum 18(4): 304-307.
39. Pattni S, Walters JR (2009) Recent advances in the understanding of bile acid malabsorption. Br Med Bull 92: 79-93.
40. Hofmann AF, Poley JR (1972) Role of bile acid malabsorption in pathogenesis of diarrhea and steatorrhea in patients with ileal resection. I. Response to cholestyramine or replacement of dietary long chain triglyceride by medium chain triglyceride. Gastroenterology 62(5): 918-934.
41. Hofmann AF (2009) Chronic diarrhea caused by idiopathic bile acid malabsorption: an explanation at last. Expert Rev Gastroenterol Hepatol 3(5): 461-464.
42. Sinha L et al (1998) Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 12(9): 839-844.
43. Westergaard H (2007) Bile Acid malabsorption. Curr Treat Options Gastroenterol 10(1): 28-33.
44. Puleston J, Morgan H, Andreyev J (2005) New treatment for bile salt malabsorption. Gut 54(3): 441-442.
45. Dignass A, van Assche A, Lindsay JO, Lémann M, Söderholm J et al (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: current management. J Crohn's Colitis 4: 28-62.
46. van Assche G, Dignass A, Reinisch W, Janneke van der Woude C, Sturm A, De Vos M, Guslandi M, Oldenburg B, Dotan I, Marteau P, Ardizzone A, Baumgart DC, D'Haens G, Gionchetti P, Portela F, Vucelic B, Söderholm J, Escher J, Koletzko S, Kolho KL, Lukas M, Mottet C, Tilg H, Vermeire S, Carbonnel F, Cole A, Novacek G, Reinshagen M, Tsianos E, Herrlinger K, Oldenburg B, Bouhnik Y, Kiesslich R, Stange E, Travis S, LindsayJ, European Crohn's and Colitis Organisation (ECCO) (2010) The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: special situations. J Crohn's Colitis 4: 63-101.
47. Calabrese C et al (2007) Mesalazine with or without cholestyramine in the treatment of microscopic colitis: randomized controlled trial. J Gastroenterol Hepatol 22(6): 809-814.
48. Jacobsen O et al (1985) Effect of enterocoated cholestyramine on bowel habit after ileal resection: a double blind crossover study. Br Med J (Clin Res Ed) 290(6478): 1315-1318.
49. Shatnawei A et al (2010) Intestinal failure management at the Cleveland Clinic. Arch Surg 145(6): 521-527.
50. Matarese LE, Steiger E (2006) Dietary and medical management of short bowel syndrome in adult patients. J Clin Gastroenterol 40(Suppl 2): S85-S93.